Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Pediatric ILD With Genetic Surfactant Dysfunction Disorders
NCT03822780Completed
- Sponsor
- Children's Hospital of Fudan University
- Start
- Jul 2017
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxychloroquine in interstitial lung disease (ILD) and surfactant dysfunction, sponsored by Children's Hospital of Fudan University. Primary endpoint: Oxygenation change at 6 months. Started Jul 2017; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
interstitial lung disease (ILD)surfactant dysfunction
Beyond the preview
Go deeper on NCT03822780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822780.